Evidence reviewed: 22 July 2026 · Author: ExtolX Editorial Team · Scientific review: Pending
Educational information for laboratory research audiences. This article does not provide medical advice, dosage or administration guidance.
Retatrutide (LY3437943) is an investigational peptide designed to activate GIP, GLP-1 and glucagon receptors. It has progressed into Phase 3 research, but it is not an approved medicine in the UK.
Key points
- The compound is a synthetic, single-molecule triple-receptor agonist of GIPR, GLP-1R and GCGR.
- Evidence from cells, animals and humans must be interpreted separately.
- Investigational; not authorised by the MHRA as a medicine. Current trial status should be checked in a recognised registry.
- Research findings do not establish that independently supplied material is equivalent to a clinical-trial product.
What is it?
Retatrutide (LY3437943) is an investigational peptide designed to activate GIP, GLP-1 and glucagon receptors. It has progressed into Phase 3 research, but it is not an approved medicine in the UK. In scientific work, identity should be established through appropriate analytical documentation rather than inferred from a product name alone.
How is it thought to work?
The three receptor systems influence overlapping aspects of glucose regulation, appetite signalling, lipid metabolism and energy expenditure. Receptor activity observed with a trial drug cannot be assumed for independently supplied research material without identity, purity and functional testing.
What does the current evidence show?
- A 338-participant, double-blind Phase 2 obesity trial reported mean weight changes at week 48 of −8.7%, −17.1%, −22.8% and −24.2% in the 1, 4, 8 and 12 mg groups, compared with −2.1% for placebo.
- A 98-participant liver-fat substudy reported mean relative liver-fat changes at week 24 of −42.9%, −57.0%, −81.4% and −82.4% across the 1–12 mg groups, compared with +0.3% for placebo.
- Phase 3 studies are ongoing. These trials assess a sponsor-manufactured investigational drug under controlled clinical conditions, not retail research material.
Evidence snapshot
| Evidence level | What it can establish | Main caution |
|---|---|---|
| Laboratory | Biochemical activity and cellular responses under defined conditions | Does not establish effects in an intact organism |
| Animal | Mechanisms and model-specific biological responses | Translation to humans is uncertain |
| Human | Outcomes in the studied population and formulation | Must not be generalised beyond the actual trial |
What remains unknown?
- Published efficacy evidence is dominated by sponsor-funded Phase 2 studies.
- Long-term outcomes and uncommon adverse events require larger and longer trials.
- Trial results do not establish equivalence with other preparations sold under the same compound name.
Regulatory and safety context
Investigational; not authorised by the MHRA as a medicine. Current trial status should be checked in a recognised registry. A research-use label does not override the way a product is presented, promoted or used. Safety information from one formulation or jurisdiction cannot be transferred automatically to another.
Frequently asked questions
Does published research prove a benefit?
No. A finding must be interpreted in the context of its model, study design, population, formulation and endpoints. Preliminary or preclinical findings are not proof of clinical benefit.
Is research material equivalent to material used in a clinical trial?
Not on the basis of a shared name. Equivalence would require evidence concerning identity, manufacture, purity, formulation, stability and biological activity.
References and further reading
- Phase 2 obesity trial — PubMed
- Phase 2 liver-fat substudy — PubMed
- Retatrutide studies — ClinicalTrials.gov
Research-use notice: ExtolX products are supplied strictly for legitimate laboratory research. They are not intended for human or veterinary use, consumption, diagnosis, treatment or prevention of disease.